Targeting the epitope spreader Pep19 by naïve human CD45RA+ regulatory T cells dictates a distinct suppressive T cell fate in a novel form of immunotherapy
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Beyond the limited scope of non-specific polyclonal regulatory T cell (Treg)-based immunotherapy, which depends largely on serendipity, the present study explored a target Treg subset appropriate for the delivery of a novel epitope spreader Pep19 antigen as part of a sophisticated form of immunotherapy with defined antigen specificity that induces immune tolerance. Methods: Human polyclonal CD4+CD25+CD127lo− Tregs (127-Tregs) and naïve CD4+CD25+CD45RA+ Tregs (45RA-Tregs) were isolated and were stimulated with target peptide 19 (Pep19)-pulsed dendritic cells in a tolerogenic milieu followed by ex vivo expansion. Low-dose interleukin-2 (IL-2) and rapamycin were added to selectively exclude the outgrowth of contaminating effector T cells (Teffs). The following parameters were investigated in the expanded antigen-specific Tregs: the distinct expression of the immunosuppressive Treg marker Foxp3, epigenetic stability (demethylation in the Treg-specific demethylated region), the suppression of Teffs, expression of the homing receptors CD62L/CCR7, and CD95L-mediated apoptosis. The expanded Tregs were adoptively transferred into an NOD/scid/IL-2Rγ−/− mouse model of collagen-induced arthritis. Results: Epitope-spreader Pep19 targeting by 45RA-Tregs led to an outstanding in vitro suppressive T cell fate characterized by robust ex vivo expansion, the salient expression of Foxp3, high epigenetic stability, enhanced T cell suppression, modest expression of CD62L/CCR7, and higher resistance to CD95L-mediated apoptosis. After adoptive transfer, the distinct fate of these T cells demonstrated a potent in vivo immunotherapeutic capability, as indicated by the complete elimination of footpad swelling, prolonged survival, minimal histopathological changes, and preferential localization of CD4+CD25+ Tregs at the articular joints in a mechanistic and orchestrated way. Conclusions: We propose human naïve CD4+CD25+CD45RA+ Tregs and the epitope spreader Pep19 as cellular and molecular targets for a novel antigen-specific Treg-based vaccination against collagen-induced arthritis.
Abstract
Purpose: Beyond the limited scope of non-specific polyclonal regulatory T cell (Treg)-based immunotherapy, which depends largely on serendipity, the present study explored a target Treg subset appropriate for the delivery of a novel epitope spreader Pep19 antigen as part of a sophisticated form of immunotherapy with defined antigen specificity that induces immune tolerance. Methods: Human polyclonal CD4+CD25+CD127lo− Tregs (127-Tregs) and naïve CD4+CD25+CD45RA+ Tregs (45RA-Tregs) were isolated and were stimulated with target peptide 19 (Pep19)-pulsed dendritic cells in a tolerogenic milieu followed by ex vivo expansion. Low-dose interleukin-2 (IL-2) and rapamycin were added to selectively exclude the outgrowth of contaminating effector T cells (Teffs). The following parameters were investigated in the expanded antigen-specific Tregs: the distinct expression of the immunosuppressive Treg marker Foxp3, epigenetic stability (demethylation in the Treg-specific demethylated region), the suppression of Teffs, expression of the homing receptors CD62L/CCR7, and CD95L-mediated apoptosis. The expanded Tregs were adoptively transferred into an NOD/scid/IL-2Rγ−/− mouse model of collagen-induced arthritis. Results: Epitope-spreader Pep19 targeting by 45RA-Tregs led to an outstanding in vitro suppressive T cell fate characterized by robust ex vivo expansion, the salient expression of Foxp3, high epigenetic stability, enhanced T cell suppression, modest expression of CD62L/CCR7, and higher resistance to CD95L-mediated apoptosis. After adoptive transfer, the distinct fate of these T cells demonstrated a potent in vivo immunotherapeutic capability, as indicated by the complete elimination of footpad swelling, prolonged survival, minimal histopathological changes, and preferential localization of CD4+CD25+ Tregs at the articular joints in a mechanistic and orchestrated way. Conclusions: We propose human naïve CD4+CD25+CD45RA+ Tregs and the epitope spreader Pep19 as cellular and molecular targets for a novel antigen-specific Treg-based vaccination against collagen-induced arthritis.
참고문헌 (40)
- Morgan ME, "Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells", Arthritis Rheum, 52, pp.2212~2221 (2005)
- Vercoulen Y, "Heat shock protein 60 reactive T cells in juvenile idiopathic arthritis : what is new?", Arthritis Res Ther, 11, pp.231~240 (2009)
- Rodríguez-Palmero M, "Effective treatment of adjuvant arthritis with a stimulatory CD28-specific monoclonal antibody", J Rheumatol, 33, pp.110~118 (2006)
- Keijzer C, "Heat shock proteins are therapeutic targets in autoimmune diseases and other chronic inflammatory conditions", Expert Opin Ther Targets, 16, pp.849~857 (2012)
- Ait-Oufella H, "Natural regulatory T cells control the development of atherosclerosis in mice", Nat Med, 12, pp.178~180 (2006)
- Bluestone JA, "Type 1 diabetes immunotherapy using polyclonal regulatory T cells", Sci Transl Med, 7, pp.315ra189~ (2015)
- Miyara M, "Treg-cell therapies for autoimmune rheumatic diseases", Nat Rev Rheumatol, 10, pp.543~551 (2014)
- Bluestone JA, "Current and future immunomodulation strategies to restore tolerance in autoimmune diseases", Cold Spring Harb Perspect Biol, 4, pp.a007542~ (2012)
- Miyara M, "Functional delineation and differentiation dynamics of human CD4+ T cells expressing the Foxp3 transcription factor", Immunity, 30, pp.899~911 (2009)
- Hoffmann P, "Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion", Blood, 108, pp.4260~4267 (2006)
- Hoffmann P, "Loss of Foxp3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation", Eur J Immunol, 39, pp.1088~1097 (2009)
- Fritzsching B, "Naive regulatory T cells : a novel subpopulation defined by resistance toward CD95L-mediated cell death", Blood, 108, pp.3371~3378 (2006)
- McMurchy AN, "Moving to tolerance : clinical application of T regulatory cells", Semin Immunol, 23, pp.304~313 (2011)
- Tang Q, "In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes", J Exp Med, 199, pp.1455~1465 (2004)
- Bluestone JA, "The therapeutic potential of regulatory T cells for the treatment of autoimmune disease", Expert Opin Ther Targets, 19, pp.1091~1103 (2015)
- Fischbach MA, "Cell-based therapeutics: the next pillar of medicine", Sci Transl Med, 5, pp.179ps7~ (2013)
- Persson GR, "Rheumatoid arthritis and periodontitis - inflammatory and infectious connections. Review of the literature", J Oral Microbiol, 4, pp.11829~ (2012)
- Arleevskaya MI, "How Rheumatoid arthritis can result from provocation of the immune system by microorganisms and viruses", Front Microbiol, 7, pp.1296~ (2016)
- Choi JI, "Epitope mapping of Porphyromonas gingivalis heat-shock protein and human heat-shock protein in human atherosclerosis", J Dent Res, 83, pp.936~940 (2004)
- Choi J, "Identification of immunoreactive epitopes of the Porphyromonas gingivalis heat shock protein in periodontitis and atherosclerosis", J Periodontal Res, 46, pp.240~245 (2011)
- Jeong E, "Predominant immunoreactivity of Porphyromonas gingivalis heat shock protein in autoimmune diseases", J Periodontal Res, 47, pp.811~816 (2012)
- Jeong E, "Porphyromonas gingivalis HSP60 peptides have distinct roles in the development of atherosclerosis", Mol Immunol, 63, pp.489~496 (2015)
- Kwon EY, "Pep19 drives epitope spreading in periodontitis and periodontitis-associated autoimmune diseases", J Periodontal Res, 51, pp.381~394 (2016)
- Joo JY, "Peptide 19 of Porphyromonas gingivalis heat shock protein is a potent inducer of low-density lipoprotein oxidation", J Periodontol, 88, pp.58~64 (2017)
- Brennan FM, "Evidence that cytokines play a role in rheumatoid arthritis", J Clin Invest, 118, pp.3537~3545 (2008)
- Haque M, "Utilizing regulatory T cells against rheumatoid arthritis", Front Oncol, 4, pp.209~ (2014)
- Zonneveld-Huijssoon E, "Bystander suppression of experimental arthritis by nasal administration of a heat shock protein peptide", Ann Rheum Dis, 70, pp.2199~2206 (2011)
- Overacre AE, "T(reg)stability : to be or not to be", Curr Opin Immunol, 39, pp.39~43 (2016)
- Ohkura N, "T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development", Immunity, 37, pp.785~799 (2012)
- Masteller EL, "Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential", Semin Immunol, 18, pp.103~110 (2006)
- Shevach EM, "Mechanisms of Foxp3+ T regulatory cell-mediated suppression", Immunity, 30, pp.636~645 (2009)
- Grant CR, "Regulatory T-cells in autoimmune diseases: challenges, controversies and--yet--unanswered questions", Autoimmun Rev, 14, pp.105~116 (2015)
- Schneider A, "Assessment of suppressive capacity by human regulatory T cells using a reproducible, bi-directional CFSE-based in vitro assay", Methods Mol Biol, 707, pp.233~241 (2011)
- Boks MA, "An optimized CFSE-based T-cell suppression assay to evaluate the suppressive capacity of regulatory T-cells induced by human tolerogenic dendritic cells", Scand J Immunol, 72, pp.158~168 (2010)
- Venken K, "A CFSE based assay for measuring CD4+CD25+ regulatory T cell mediated suppression of auto-antigen specific and polyclonal T cell responses", J Immunol Methods, 322, pp.1~11 (2007)
- Raker VK, "Tolerogenic dendritic cells for regulatory T cell induction in man", Front Immunol, 6, pp.569~ (2015)
- Trzonkowski P, "Hurdles in therapy with regulatory T cells", Sci Transl Med, 7, pp.304ps18~ (2015)
- Brusko TM, "Human antigen-specific regulatory T cells generated by T cell receptor gene transfer", PLoS One, 5, pp.e11726~ (2010)
- Gratz IK, "Organ-specific and memory Treg cells: specificity, development, function, and maintenance", Front Immunol, 5, pp.333~ (2014)
- Chaudhry A, "Control of inflammation by integration of environmental cues by regulatory T cells", J Clin Invest, 123, pp.939~944 (2013)